Physician profile
Daniel J Frank
NPI 1437194610
$1,770.37
in general payments reported to CMS, 2019-2025
28 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $15.61 · 2021: $180 · 2022: $571 · 2023: $534 · 2024: $226 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.23 |
| Education | $105.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $315.00 | 2019-2024 | Phesgo, Kadcyla, Perjeta |
| Gilead Sciences, INC. | $251.65 | 2021-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $179.36 | 2021-2024 | |
| Pfizer INC. | $98.17 | 2022-2025 | |
| Amgen INC. | $81.41 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $71.05 | 2019-2023 | Keytruda |
| Lilly USA, LLC | $61.43 | 2022 | |
| Celgene Corporation | $60.38 | 2023-2024 | Pomalyst |
| Myriad Genetic Laboratories, INC. | $53.24 | 2024 | Myrisk |
| E.R. Squibb & Sons, L.L.C. | $48.27 | 2023-2025 | Opdivo, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $46.11 | 2022-2023 | Iclusig |
| Emd Serono, INC. | $43.93 | 2022-2023 | Bavencio |
| G1 Therapeutics, INC. | $43.42 | 2022-2023 | Cosela |
| Seagen INC. | $43.41 | 2022 | |
| Cti Biopharma Corp. | $42.97 | 2023 | Vonjo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $40.53 | 2022-2023 | Erleada |
| Abbvie INC. | $34.16 | 2023-2025 | |
| Exelixis INC. | $31.46 | 2022 | |
| Glaxosmithkline, LLC. | $27.49 | 2023 | Zejula, Jemperli |
| Daiichi Sankyo INC. | $27.34 | 2024 | Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $25.76 | 2022 | |
| Puma Biotechnology, INC. | $25.74 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.49 | 2023 | Givlaari |
| Coherus Oncology, INC. | $22.49 | 2021 | |
| Karyopharm Therapeutics INC. | $21.05 | 2021 | |
| Genzyme Corporation | $18.81 | 2022 | |
| Array Biopharma INC | $17.31 | 2022 | |
| Blueprint Medicines Corporation | $15.94 | 2023 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.